How does bioprocessing for CGT differ from traditional biologics?

Traditional bioprocessing focuses on secreting proteins (like antibodies) from a cell. In contrast, cell and gene therapy (CGT) manufacturing often treats the cell itself as the product, or uses viral vectors for delivery. This requires a radical shift in bioprocess technology, moving from "scale-up" (larger volumes) to "scale-out" (numerous parallel small-scale batches).

The complexity of handling living cells—particularly in autologous therapies where the patient's own cells are the starting material—introduces significant logistical and technical challenges. Maintaining a "chain of custody" and "chain of identity" through every step of the bioprocess is just as critical as the biological yield itself.

How are Viral Vector Manufacturing Platforms evolving in 2024?

The bottleneck in the CGT sector remains the production of AAV and lentiviral vectors. In 2024, Viral Vector Manufacturing Platforms are transitioning toward stable cell lines and suspension-based bioreactors. This move away from adherent, transient transfection methods is significantly improving throughput and lowering the astronomical costs associated with gene therapies.

What is the outlook for 2025?

For 2025, we anticipate a rise in automated "point-of-care" bioprocessing. These are closed, self-contained units capable of processing patient cells in a hospital setting rather than a centralized factory. This "decentralized manufacturing" model could be the key to making expensive therapies accessible to a broader patient population while reducing transport-related risks.

Author: Sofiya Sanjay

Designation: Healthcare Research Consultant, Market Research Future

About: At Market Research Future (MRFR), we enable organizations to unravel complex industries through Cooked Research Reports (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. Our studies across products, technologies, applications, end users, and global to country-level segments help decision-makers see more, know more, and do more.

Contact: 99 Hudson Street, 5th Floor, New York, NY 10013, USA | (855) 661-4441 (US) | +44 1720 412 167 (UK) | +91 2269738890 (APAC) | info@marketresearchfuture.com